GITR Bioassay

Creative Biolabs is a professional collaborator for biotechnology and pharmaceutical companies that have developed a comprehensive service chain in evaluating new immunotherapies targeting immune checkpoints. With in-depth expertise in antibody functional analysis, we offer GITR Bioassay, which is based on the reporter gene assay, to measure the potency and activity of antibodies targeting GITR and to explore the mechanism of action (MOA). We are dedicated to helping our worldwide customers strengthen the understanding of their antibody candidates in a low-cost manner.

Introduction to GITR

GITR, which belongs to the TNFR family, is a type I transmembrane protein that can be constitutively expressed at high levels on regulatory T cells (Tregs) and at low levels on naïve and memory T cells. Its ligand, GITRL is also a member of the TNF superfamily and is expressed on a variety of cells, such as T cells, several dendritic cells (DCs), and macrophages. The studies have shown that GITRL is associated with activated antigen presenting cell (APC) activation and its binding to GITR can affect the Treg function in immune systems. Meanwhile, research conducted on GITR has indicated that GITR-GITRL interaction can prevent the function of Treg to promote graft survival. GITR modulation in preclinical tumor models has shown compelling antitumor activity which is attributed to both its costimulatory role on CD4⁺ and CD8⁺ T cells, as well as inhibition or depletion of intratumoral Tregs. Development of agonistic antibodies targeting GITR for cancer immunotherapy is a promising strategy. The Fc of the antibody can interact with both activating and inhibitory Fcγ receptors, resulting in the stimulation of antibody-dependent cell-mediated clearing of target cells.

Fig. 1 GITR functions as a modulator in antitumor immunity.¹

GITR Bioassay Provided by Creative Biolabs

At Creative Biolabs, we can provide a panel of immune checkpoint interaction analysis services, which has been widely used for evaluating the interaction, potency, and stability of antibodies targeting a range of disease-related immune checkpoints, such as GITR. GITR Bioassay is a bioluminescent cell-based assay that overcomes the limitations of current traditional methods (such as complex assay protocols, unqualified assay reagents, and dependence on donor primary cells). It can be used to measure antibody potency as well as investigate the MOA. Our services are characterized by:

• Excellent expert team to offer real-time technical guidance
• Advanced assay platforms to promote the data output
• Timely data feedback to facilitate the process of your project

With over years of experience in immunotherapy development, Creative Biolabs offers a large collection of immune checkpoint reporter gene assays to facilitate in vitro antibody functional analysis. Our client-focused, integrated team will anticipate challenge, overcome difficulties and successfully convert various potential candidate antibodies into clinical trials. For more information, please feel free to contact us or send us an inquiry.

Reference

1. Comito, Francesca, et al. "Emerging novel therapeutic approaches for treatment of advanced cutaneous melanoma." Cancers 14.2 (2022): 271.

For Research Use Only.